Compare Stocks

Enter up to five stock symbols separated by a comma or space (e.x BAC,WFC,JPM,LON:BARC).
 

 OptheaTrilogy International PartnersBEXIMCO PHARMAC/S GDR REGSPharmaxisAllergy Therapeutics
SymbolASX:OPTTSE:TRLLON:BXPASX:PXSLON:AGY
Price Information
Current PriceA$0.77C$2.94GBX 43A$0.23GBX 12
52 Week RangeN/ABuyBuyN/ABuy
Analyst Ratings
Consensus RecommendationN/ABuyBuyN/ABuy
Consensus Price TargetN/AC$3.50N/AN/AGBX 37.50
% Upside from Price TargetN/A19.05% upsideN/AN/A212.50% upside
Trade Information
Market Cap$190.80 millionC$170.30 million£174.39 million$90.69 million£79.52 million
BetaN/AN/AN/AN/AN/A
Average VolumeN/A37,97735,555328,880167,682
Sales & Book Value
Annual Revenue$187,574.00C$783.23 millionN/A$6.60 million£72.82 million
Price / Sales1,017.210.22N/A13.751.05
CashflowA$0.15 per shareC$1.81 per shareN/AA$0.09 per shareGBX 4.39 per share
Price / Cash4.971.62N/A2.642.74
Book ValueA$0.16 per shareC($1.28) per shareN/AA$0.04 per shareGBX 7 per share
Price / Book4.81-2.30N/A5.750.02
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSA($0.08)C($0.52)N/AA($0.07)GBX (0.50)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E Ratio
P/E GrowthN/AC($65.33)N/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AC$0.02GBX 0.01N/AN/A
Dividend YieldN/A0.68%0.02%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A N/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A38.08%47.11%6.20%
Current Ratio5.24%1.08%1.17%12.35%3.74%
Quick Ratio5.22%0.81%0.36%11.65%3.08%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A1,8214,20064500
Shares Outstanding249.42 million57.93 million405.56 million394.32 million636.17 million
Next Earnings DateN/A8/12/2019 (Confirmed)N/AN/A9/25/2019 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
 OptheaTrilogy International PartnersBEXIMCO PHARMAC/S GDR REGSPharmaxisAllergy Therapeutics

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel